信迪利单抗联合FOLFOX方案治疗晚期不可切除原发性肝癌疗效及安全性分析  

Efficacy and Safety of Sintilimab Combined with FOLFOX Regimen in the Treatment of Advanced Unresectable Primary Liver Cancer

作　　者：陈园园 安慧娟 王晓聪 CHEN Yuanyuan;AN Huijuan;WANG Xiaocong(Pingdingshan Traditional Chinese Medicine Hospital,Pingdingshan,467000)

机构地区：[1]河南省平顶山市中医医院,467000

出　　处：《实用癌症杂志》2024年第9期1560-1563,共4页The Practical Journal of Cancer

摘　　要：目的分析信迪利单抗联合FOLFOX方案(奥沙利铂+亚叶酸钙+氟尿嘧啶)治疗晚期不可切除原发性肝癌的疗效及安全性。方法回顾性分析83例晚期不可切除原发性肝癌患者的临床资料,将48例采用FOLFOX方案治疗的患者纳入对照组,35例采用信迪利单抗联合FOLFOX方案治疗的患者纳入联合组。比较两组患者临床疗效、肿瘤标志物[甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原-199(CA-199)]水平、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))及用药不良反应。结果治疗后,联合组患者疾病控制率(DCR)高于对照组(P<0.05)。治疗后,两组患者AFP、CEA、CA-199水平均较治疗前降低,且联合组低于对照组(P<0.05)。治疗后,联合组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较治疗前升高,CD8^(+)较治疗前降低;对照组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较治疗前降低,CD8^(+)较治疗前升高(P<0.05)。治疗过程中,两组患者胃肠道反应、血液系统反应、神经系统反应、变应性致敏、甲状腺功能异常发生率比较,差异无统计学意义(P>0.05)。结论信迪利单抗联合FOLFOX方案治疗晚期不可切除原发性肝癌的临床疗效良好,可有效改善患者肿瘤标志物水平及机体免疫功能,且安全性良好。Objective To analyze the efficacy and safety of sintilimab combined with FOLFOX regimen(oxaliplatin+calcium folinate+fluorouracil)in the treatment of advanced unresectable primary liver cancer.Methods The clinical data of 83 patients with advanced unresectable primary liver cancer were retrospectively analyzed.48 patients treated with FOLFOX regimen were included in the control group,and 35 patients treated with sintilimab combined with FOLFOX regimen were included in the combination group.The clinical efficacy,levels of tumor markers[alpha fetoprotein(AFP),Carcinoembryonic antigen(CEA),carbohydrate antigen-199(CA-199)],T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and adverse drug reactions were compared between the 2 groups.Results After treatment,the disease control rate(DCR)of the combination group patients was higher than that of the control group(P<0.05).After treatment,the levels of AFP,CEA,and CA-199 in both groups of patients decreased compared to before treatment,and the combination group was lower than the control group(P<0.05).After treatment,the CD3^(+),CD4^(+),CD4^(+)/CD8^(+)levels in the combination group increased compared to before treatment,while CD8^(+)levels decreased compared to before treatment.The CD3^(+),CD4^(+),CD4^(+)/CD8^(+)levels in the control group decreased compared to before treatment,while CD8^(+)levels increased compared to before treatment(P<0.05).During the treatment process,there was no statistical significant difference in the incidence of gastrointestinal reactions,hematological reactions,neurological reactions,allergic sensitization,and thyroid dysfunction between the 2 groups of patients(P>0.05).Conclusion Sintilimab combined with FOLFOX regimen has good clinical efficacy in the treatment of advanced unresectable primary liver cancer,which can effectively improve the level of tumor markers and immune function of patients,and has good safety.

关 键 词：原发性肝癌 奥沙利铂 亚叶酸钙 氟尿嘧啶 信迪利单抗 

分 类 号：R735.7[医药卫生—肿瘤]